Edwards Lifesciences Launches SAPIEN 3 System in Europe
Edwards Lifesciences has taken a notable step in treating congenital heart disease with the introduction of the SAPIEN 3 transcatheter pulmonary valve implantation (TPVI) system, featuring the cutting-edge Alterra adaptive prestent. This new offering aims to broaden minimally invasive treatment options for a wider range of patients.
Enhancing Treatment Options
The SAPIEN 3 TPV system, equipped with Alterra, recently received CE mark approval for patients suffering from severe pulmonary regurgitation. This state-of-the-art system has been carefully engineered to accommodate a variety of anatomical complexities, thus expanding the clinical benefits provided by the SAPIEN 3 transcatheter pulmonary valve to more patients.
Expert Perspectives on Patient Advantages
Professor Damien Kenny, a consultant congenital cardiologist, pointed out the difficulties encountered by patients with congenital heart issues. He noted that many of these individuals often undergo several invasive surgeries, which can severely impact their quality of life. By adding the Alterra prestent to the SAPIEN 3 valve platform, doctors can offer minimally invasive therapies, potentially postponing the necessity for future open-heart surgeries.
Revolutionary Technology in Action
The integration of the established SAPIEN 3 transcatheter valve with the sophisticated Alterra prestent marks a significant advancement in valve technology. This prestent effectively accommodates variations in the size and shape of the right ventricular outflow tract, creating a consistent landing zone for the SAPIEN 3 valve. Additionally, the specially engineered delivery system allows for seamless navigation to the pulmonary artery and provides unique features for recapturing and repositioning the valve, if needed.
Catering to Diverse Patient Needs
Gregory Servotte, senior vice president of transcatheter heart valves in Europe at Edwards, underscored the wide-ranging needs of those requiring pulmonic heart valve replacements. He noted that this patient demographic faces intricate challenges, including adolescents and adults with conditions such as Tetralogy of Fallot. Servotte expressed pride in the progress made with the SAPIEN 3 and Alterra, underscoring Edwards' commitment to advancing life-saving innovations that meet the needs of patients with structural heart disease.
Regulatory Information
The 29mm Edwards SAPIEN 3 TPV system with Alterra adaptive prestent is specifically designed for patients suffering from severe pulmonary regurgitation and who either have a native or surgically repaired right ventricular outflow tract. It is also clinically suitable for those needing pulmonary valve replacement.
About Edwards Lifesciences
As a pioneer in structural heart innovation, Edwards Lifesciences is dedicated to improving patient outcomes through groundbreaking technologies and strong collaborations with healthcare professionals. Their focus on a patient-centered culture inspires employees to create transformative innovations to assist those who need it most. You can find out more about their products at www.edwards.com and keep up with the latest updates through their LinkedIn and X accounts.
Frequently Asked Questions
What does the SAPIEN 3 TPV system do?
The SAPIEN 3 TPV system serves as a transcatheter pulmonary valve implantation system aimed at treating severe pulmonary regurgitation.
How does the Alterra prestent enhance treatment?
The Alterra prestent provides a stable landing zone for the SAPIEN 3 valve, accommodating different anatomical shapes in the heart.
Who are the primary patients for the SAPIEN 3 system?
The main beneficiaries of the SAPIEN 3 system are individuals with congenital heart conditions, especially those needing pulmonic valve replacements.
What benefits does minimally invasive therapy provide?
Minimally invasive therapy can significantly shorten recovery times while enhancing quality of life by reducing the need for open-heart surgeries.
Where can I find more information about Edwards Lifesciences?
You can learn more about their innovations and updates by visiting their website at www.edwards.com.
